Stoke Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $4,894 | $4,831 | $4,216 | $2,802 |
Gross Profit | 3,783 | 3,721 | 3,103 | 1,587 |
EBITDA | -30,003 | -28,794 | -27,809 | -28,962 |
EBIT | -30,543 | -29,904 | -28,922 | -30,177 |
Net Income | -26,430 | -25,695 | -26,374 | -26,958 |
Net Change In Cash | 4,894 | 4,831 | 4,216 | 2,802 |
Free Cash Flow | -21,718 | -17,523 | -24,578 | -20,878 |
Cash | 150,016 | 193,551 | 178,581 | 191,442 |
Basic Shares | 56,341 | 55,765 | 46,246 | 44,958 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $8,780 | $12,405 | $3,000 | $0 |
Gross Profit | 8,780 | 12,405 | -2,230 | -1,926 |
EBITDA | -112,304 | -102,810 | -85,091 | -52,156 |
EBIT | -114,773 | -104,356 | -86,065 | -53,044 |
Net Income | -104,699 | -93,110 | -84,711 | -50,611 |
Net Change In Cash | 8,780 | 12,405 | 3,000 | 0 |
Cost of Revenue | -31,339 | -142,049 | 64,837 | |
Free Cash Flow | -82,683 | -35,828 | -68,107 | -43,271 |
Cash | 191,442 | 113,556 | 144,895 | 287,308 |
Basic Shares | 43,994 | 38,897 | 36,739 | 33,488 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.46 |
2024-06-30 | -$0.46 |
2024-03-31 | -$0.57 |
2023-12-31 | -$0.60 |
